India, Sept. 4 -- Fortunes can change quietly. At the start of the year, Contineum Therapeutics Inc. (CTNM) was trading near its lows. Today, its shares are at a 52-week high. Behind that rise is a clear and disciplined focus: advancing the clinical programs with the greatest potential and the best chance of success.
The company's lead drug candidate is PIPE-791, which is in a global Phase 2 trial for the treatment of patients with idiopathic pulmonary fibrosis, dubbed PROPEL-IPF.
When did we first highlight CTNM?
Contineum was featured on our site on February 18, 2025, when it was trading around $7.81.
Our report focused on the company's clinical pipeline, including PIPE-791, which was then being evaluated in a Phase 1b positron emissi...